Venture Capital for German Biotech Firms Plummeted in 2025
Germany’s biotechnology sector, once a beacon of scientific innovation and economic promise, is confronting a sobering reality. New data reveals that venture capital flowing into German biotech firms dropped sharply in 2025, raising questions about the country’s ability to translate world-class research into commercial success.
According to a joint report released by consultancy firm EY and industry association BIO Deutschland, biotech companies in Germany raised approximately €1.8 billion — roughly $2 billion — from investors and through stock market share issues in 2025. That figure represents a 5 percent decline from 2024, but the headline number masks a far more dramatic contraction in early-stage funding.
Venture capital investments, the lifeblood of emerging biotech companies, plummeted by a staggering one-third to just €601 million. The study found that available funding increasingly concentrated on a small number of well-established firms, leaving younger and riskier enterprises struggling to secure the capital they need to survive.
“Germany has a problem with the value creation of biotechnological inventions and developments,” said Viola Bronsema, head of BIO Deutschland. “Scientific excellence is undisputed, but so far, it has not led to corresponding economic strength.”
The findings paint a troubling picture for a sector that employs just under 60,000 people across the country and includes household names such as BioNTech, Qiagen, and Evotec. Sector-wide turnover slipped 1 percent to €12 billion in 2025, while spending on research and development also declined — a worrying trend for an industry that depends on sustained R&D investment to bring new therapies and technologies to market.
German biotech firms work across a wide spectrum of disciplines, from gene and cell therapies, vaccines, and antibodies to solutions for industry, agriculture, and environmental protection. But the path from laboratory discovery to commercial product is expensive and time-consuming, which is why these companies rely heavily on external funding — most of which has historically come from investors in the United States.
Without sufficient capital, the report warns, many young German biotech companies face an existential dilemma. Unable to bring emerging technologies to clinical maturity, they are increasingly forced to sell to international investors at an early stage or relocate their operations abroad. The consequence is a potential exodus of talent and intellectual property that could hollow out Germany’s innovation ecosystem over time.
The funding squeeze reflects broader economic headwinds in Germany, where sluggish growth and persistent uncertainty have dampened investor appetite across multiple sectors. But for biotech, the stakes are uniquely high. Breakthroughs in areas like personalised medicine, mRNA technology, and synthetic biology require patient capital willing to accept long development timelines and significant risk — precisely the kind of investment that is now drying up.
Industry observers warn that if the trend continues, Germany risks falling further behind the United States and other competitors in the global biotech race. The country’s strength in basic science research, anchored by world-renowned universities and research institutes, may not be enough to sustain a vibrant commercial biotech sector without a corresponding commitment from investors and policymakers to support the translation of discoveries into viable businesses.
For now, Germany’s biotech firms find themselves caught between scientific excellence and economic uncertainty — a gap that venture capital alone may no longer be willing to bridge.
Image Source: GHANA BUSINESS NEWS
